Impact of angiotensin II receptor antagoniston on adriamycin-induced cardiomyopathy

Impact of angiotensin II receptor antagoniston on adriamycin-induced cardiomyopathy - Impact of ARB on adriamycin-induced cardiomyopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005066

Enrollment

100

Registered

2011-04-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marignancy patients who will treat with adriamycin

Interventions

angiotensin II receptor antagonist(olmesartan) no medication (olmesartan)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Malignancy patients who will treat with adrimycin

Exclusion criteria

Exclusion criteria: 1. Patients with obstructive hypetorophic cardiomyopathy 2. Allergy of ARB 3. Patients with pregnancy or likelihood of pregnancy 4. Patients with bilateralrenal artery stenosis 5. Patients receiving ARB

Design outcomes

Primary

Measure	Time frame
Systolic and diastolic function by means of echocardiography	—

Secondary

Measure	Time frame
Regional left ventricular myocrdial function by menas of speckle-trakicng method.	—

Countries

Japan

Contacts

Public ContactHidekazu Tanaka

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine, Department of Internal Medicine

078-382-5846

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026